Skip to main content
. 2020 Oct 20;10:17799. doi: 10.1038/s41598-020-74185-8

Table 1.

Baseline characteristics of the populations studied.

Population 1 Population 2 Healthy donors p
(n = 30) (n = 32) (n = 24)
Female; n (%) 25 (83.33) 27 (84.38) 20 (83.33) 1
Age; p50 [p25–p75] 52 [39–70] 52 [43 – 60] 52 [36–64] 0.79
BMI; p50 [p25–p75] 26.46 [23.5–29.27] 26.78 [22.87–30.26] 28.23 [25.05–29.37] 0.646
RA/UA; n (%) 30 (100)/0 (0) 21 (65.63)/11 (34.38)  < 0.001
Disease duration (months); p50 [p25–p75] 6.48 [2.76–8.83] 2.78 [2–7.81] 0.060
RF positive; n (%) 22 (73.33) 16(50) 0.059
ACPA positive; n (%) 20(66.67) 16(50) 0.184
DAS28; p50 [p25–p75] 5.12 [3.89–5.8] 3.91 [2.98–6.34] 0.049
HAQ; p50 [p25–p75] 1.06 [0.62–1.62] 1 [0.81–1.37] 0.970

p50: median; p25-p75: interquartile range; BMI: body mass index; RA: rheumatoid arthritis; UA: undifferentiated arthritis; RF: rheumatoid factor; ACPA: anti-citrullinated protein antibodies; DAS28: disease activity score estimated with 28 joint count. HAQ: health assessment questionnaire.